VERU INC. - COMMON STOCK

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

12 7 2022 15:30:00 提供 Nasdaq GlobeNewswire

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients

06 7 2022 06:30:45 提供 Nasdaq GlobeNewswire

Veru Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

24 6 2022 15:30:00 提供 Nasdaq GlobeNewswire

Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS

07 6 2022 05:30:00 提供 Nasdaq GlobeNewswire

Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

06 6 2022 05:30:00 提供 Nasdaq GlobeNewswire

Veru to Present Three Presentations at the 2022 American Society for Clinical Oncology Annual Meeting on June 3-7

31 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

Veru to Participate in Fireside Chat at the Jefferies Healthcare Conference on June 8, 2022

25 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients

18 5 2022 07:30:01 提供 Nasdaq GlobeNewswire

Veru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022

17 5 2022 07:30:01 提供 Nasdaq GlobeNewswire

Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization

12 5 2022 05:30:00 提供 Nasdaq GlobeNewswire

FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients

11 5 2022 05:30:00 提供 Nasdaq GlobeNewswire

FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study

02 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

Veru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12th

28 4 2022 07:30:01 提供 Nasdaq GlobeNewswire

Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases

25 4 2022 07:30:00 提供 Nasdaq GlobeNewswire

Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy

11 4 2022 05:30:00 提供 Nasdaq GlobeNewswire

Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer Conference

04 3 2022 07:30:00 提供 Nasdaq GlobeNewswire

Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022

01 3 2022 07:30:01 提供 Nasdaq GlobeNewswire

Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium

17 2 2022 07:30:00 提供 Nasdaq GlobeNewswire

Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned

14 2 2022 07:30:00 提供 Nasdaq GlobeNewswire

Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%

09 2 2022 05:30:00 提供 Nasdaq GlobeNewswire